In a significant development, Australia-based pharmaceutical player SUDA Pharmaceuticals Limited (ASX: SUD) has recently signed deals with two renowned entities - Sanofi Aventis Groupe and Laboratorios Ordesa S.L.
The deals followed the agreement finalised with a specialty phyto-cannabinoid biopharmaceutical firm, Cann Pharmaceutical Australia Ltd in October 2019.
SUDA is an international leader engaged in reformulating and providing medication via the oral mucosa. SUDA creates low-risk oral sprays by making use of its exclusive OroMist® technology to recast the existing medications. The Company has enhanced the bioavailability of the medications from 25 per cent to up to 95 per cent via its proprietary OroMist® technology.
The Company’s technology overcomes the factors that affect the bioavailability of capsules, tablets and pills, such as food effect, enzymatic degradation, drug metabolism; first pass metabolism and others.
SUDA’s CEO, Dr Michael Baker was recently interviewed on Finance News Network, where he talked about the Company’s plans to commercialise its lead product ZolpiMistTM worldwide and to develop Anagrelide, for the treatment of cancer.
Listen to the Interview Here
Feasibility Agreement with Sanofi
SUDA has recently entered into a feasibility agreement with Sanofi to investigate the feasibility of its OroMist® technology and Sanofi’s chosen active ingredient. Under the feasibility agreement, the Company will conduct a fully funded feasibility study, which will terminate on 30th March 2021.
Both SUDA and Sanofi are likely to enter into a further collaboration subject to the outcomes of the feasibility study.
Sanofi is a global biopharmaceutical company headquartered in Paris, which focuses on human health. It offers innovative treatments to ease suffering and fight pain and prevents diseases with vaccines. Moreover, it stands by the millions of patients suffering from long-term chronic conditions and few affected by rare diseases.
Co-Development Deal with Ordesa
The Company has also entered into an option agreement and a fully funded feasibility study with a Spanish pharmaceutical company - Ordesa, which focuses on health, nutrition and well-being.
The feasibility study will be fully financed by the Spanish player, and the Company will get ~$140,000 (USD 100,000) as an upfront option fee.
Ordesa has a history of over 75 years, providing the finest products in infant feeding. It offers baby milk and cereals, a wide range of nutritional supplements covering the whole paediatric age, a broad array of products for women, numerous nutritional supplements for adults and a new line for child atopic skin care.
Under the deal, SUDA and Ordesa intend to jointly create a significant consumer product for the growing paediatric market. The Company expects that the product will benefit from a better patient delivery route and which could, possibly, also benefit from the OroMist® technology’s excellence in less requirement of drug and speed of onset of action.
Once the initial feasibility study gets successfully completed (or as decided by the parties), the Spanish firm may elect to exercise its option or enlarge the scope of work for a complete development of the product which will be financed by Ordesa.
The full development of the product and all the intellectual property that arises out of the study will be jointly owned by the two parties, while the trademark of the product will be Ordesa’s property.
Both the entities will discuss on a definitive agreement for the licence, development and supply of the product, and will work collectively through joint committees to oversee the commercialisation and development of the consumer product.
The deals with these major pharmaceutical players validate SUDA’s potential to flourish in the high-value markets. The Company is ideally placed to leverage its strong network to tap other business opportunities.
Take a look at SUDA’s Drug Delivery Partnerships for its key product, ZolpiMistTM Here.
SUD closed the trading session at $0.060 on 21 January 2020.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. We are neither licensed nor qualified to provide investment advice through this platform.